Swedish Orphan Biovitrum AB Banner Image

Swedish Orphan Biovitrum AB

  • Ticker
  • Industry Drug Manufacturers - Major More
  • Sector Healthcare More
Swedish Orphan Biovitrum AB Logo Image
  • 1001-5000 Employees
  • Based in Solna, Sweden
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocyticMore lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
4.7 / 5.0 (51)

Swedish Orphan Biovitrum AB reports have an aggregate usefulness score of 4.7 based on 51 reviews.

Swedish Orphan Biovitrum AB

Most Recent Annual Report

Swedish Orphan Biovitrum AB
MOST RECENT 2022 Annual Report

Older/Archived Annual Reports

Swedish Orphan Biovitrum AB Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!